Back
ESC Premium Access

The validity of heart failure diagnoses at hospital-discharge and ambulatory evaluation visits: insights from two Norwegian local hospitals

Session: Chronic heart failure e-posters
Topic: Diagnostic Methods
Speaker: Doctor A. Ofstad (Gjettum, NO)
Event: ESC Congress 2021 - The Digital Experience

Presentation

0

About the speaker

Doctor Anne Pernille Ofstad

Baerum Hospital Vestre Viken Trust, Gjettum (Norway)
1 presentation
0 follower

218 more presentations in this session

Intermittent therapy with levosimendan in patients with advanced heart failure

Speaker: Professor M. Weis (Munich, DE)

Access
Abstract
Slides
0
Thumbnail

Differences in long-term all-cause and cardiovascular mortality according to heart failure aetiology in ambulatory patients

Speaker: Doctor G. Spitaleri (Badalona, ES)

Access
Abstract
Slides
0
Thumbnail

Comparing the central arterial stiffness indices in the decompensated and compensated states of heart failure: a cohort study

Speaker: Assistant Professor G. Youssef (Cairo, EG)

Access
Abstract
Slides
0
Thumbnail

Opportunities for clinician education in the pharmacotherapy of stable heart failure

Speaker: Doctor P. Murray (Dublin, IE)

Access
Abstract
Slides
0
Thumbnail

Systolic blood pressure visit-to-visit variability and clinical outcomes of heart failure with preserved ejection fraction

Speaker: Doctor Q. Zhang (Tianjin, CN)

Access
Abstract
Slides
0
Thumbnail

Access the full session

Chronic heart failure e-posters

Speakers: Doctor A. Ofstad, Professor M. Weis, Doctor G. Spitaleri, Assistant Professor G. Youssef, Doctor P. Murray...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

27 August 2021

ESC Premium Access

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints

27 August 2021

This platform is supported by

logo Novo Nordisk